Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

Nobel Laureate for Chemistry to visit UFS
2017-10-28

Description: Prof Levitt read more Tags: Prof Levitt read more

Prof Michael Levitt will be hosted by the UFS from
14 to 16 November 2017, where he will present the
first lecture in the Vice-Chancellor’s
Prestige Lecture Series.
Photo: Supplied

It is a great honour for the University of the Free State (UFS) to host Prof Michael Levitt, recipient of the 2013 Nobel Prize for Chemistry, which he shares with Marti Karplus and Arieh Warshel.

The trio received the Nobel Prize for their development of multiscale models used for complex chemical systems. “Being awarded the Nobel Prize is a unique and marvellous experience that no one can prepare for or could in any way know what to except,” said Prof Levitt during his 2013 Nobel Lecture at the Stanford University School of Medicine.

First lecture in Vice-Chancellor’s lecture series

The South African-born Nobel Laureate and Academy of Science of South Africa (ASSAf) Visiting Scholar will present the first lecture, Birth and Future of Multiscale Modelling of Macromolecules, in the Vice-Chancellors Prestige Lecture Series at the UFS on 14 November 2017. Prof Levitt is well-known for developing approaches which predict macromolecular structures.

He is one of many distinguished academics invited annually by ASSAf to deliver lectures as part of the Distinguished Visiting Scholars’ Programme, presented by ASSAf at universities across the country.

Pioneer in research of molecular dynamics

Prof Levitt is a biophysicist and a professor of Biology at Stanford University. He was one of the earliest researchers to conduct research on molecular dynamics stimulations of DNA and proteins. “My post-prize ambitions are twofold and probably inconsistent: (1) Work single-mindedly as I did in the mid-1970s on hard problems, and (2) Help today’s young scientists gain the recognition and independence which my generation enjoyed,” said Prof Levitt.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept